4-O-Mono-Fructosyl Phlorizin Reduces Renal SGLT2 Immunoreactivity and Improves Metabolic Dysfunction in a High-Fat Diet/Streptozotocin-Induced Diabetic Mice

Diabetes mellitus (DM) is a chronic metabolic disorder characterized by persistent hyperglycemia, which, together with associated metabolic abnormalities, contributes to progressive damage in multiple organ systems. The development of effective and safe therapeutic alternatives remains a major research priority. Phlorizin is a dihydrochalcone that inhibits sodium-glucose cotransporter 1 and 2 (SGLT1 and SGLT2). 4-O-mono-fructosyl phlorizin (4PHF) was synthesized from phlorizin by transfructosylation with a levansucrase from Paraburkholderia phymatum (KesL) using sucrose as a donor. The in vivo antidiabetic effect of 4PHF was evaluated using a murine model of experimental diabetes (high-fat diet followed by a single streptozotocin dose). The groups were treated for 28 days as follows: the diabetic control group received distilled water, the 4PHF-treated diabetic group received 4PHF, the reference treatment group received the SGLT2 inhibitor dapagliflozin, and the non-diabetic control group received a standard diet. 4PHF exhibited a tendency to reduce blood glucose levels, increase urinary glucose excretion, and improve the lipid profile by lowering triglycerides and total cholesterol. 4PHF showed attenuation of hepatic and renal histopathological alterations. Immunohistochemistry revealed a marked decrease in SGLT2 expression and in the number of SGLT2-positive tubules in treated animals, suggesting that the treatment may modulate SGLT2 inhibition. Overall, 4PHF emerges as a promising therapeutic candidate for diabetes mellitus, as it reduces renal SGLT2 expression, improves metabolic dysfunction, and attenuates diabetes-induced hepatic and renal damage.

Authors

Publication Details

Journal
Scientia Pharmaceutica
Published
2026-11-18
DOI
https://doi.org/10.3390/scipharm94040115
Primary Topic
Natural Antidiabetic Agents Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

4-O-Mono-Fructosyl Phlorizin Reduces Renal SGLT2 Immunoreactivity and Improves Metabolic Dysfunction in a High-Fat Diet/Streptozotocin-Induced Diabetic Mice

Omar Ricardo Torres-González, Azucena Herrera-González, Eduardo Padilla‐Camberos, Iván Moisés Sánchez-Hernández et al.
1 links
Scientia Pharmaceutica
Natural Antidiabetic Agents Studies
article

4-O-Mono-Fructosyl Phlorizin Reduces Renal SGLT2 Immunoreactivity and Improves Metabolic Dysfunction in a High-Fat Diet/Streptozotocin-Induced Diabetic Mice

Omar Ricardo Torres-González, Azucena Herrera-González, Eduardo Padilla‐Camberos, Iván Moisés Sánchez-Hernández, Clarita Olvera, Javier Arrizón, Angélica Sofía González-Garibay, José Guadalupe Torres-Tolentino, Sinaí Guadalupe Coronado-Gutiérrez
article en

Abstract

Diabetes mellitus (DM) is a chronic metabolic disorder characterized by persistent hyperglycemia, which, together with associated metabolic abnormalities, contributes to progressive damage in multiple organ systems. The development of effective and safe therapeutic alternatives remains a major research priority. Phlorizin is a dihydrochalcone that inhibits sodium-glucose cotransporter 1 and 2 (SGLT1 and SGLT2). 4-O-mono-fructosyl phlorizin (4PHF) was synthesized from phlorizin by transfructosylation with a levansucrase from Paraburkholderia phymatum (KesL) using sucrose as a donor. The in vivo antidiabetic effect of 4PHF was evaluated using a murine model of experimental diabetes (high-fat diet followed by a single streptozotocin dose). The groups were treated for 28 days as follows: the diabetic control group received distilled water, the 4PHF-treated diabetic group received 4PHF, the reference treatment group received the SGLT2 inhibitor dapagliflozin, and the non-diabetic control group received a standard diet. 4PHF exhibited a tendency to reduce blood glucose levels, increase urinary glucose excretion, and improve the lipid profile by lowering triglycerides and total cholesterol. 4PHF showed attenuation of hepatic and renal histopathological alterations. Immunohistochemistry revealed a marked decrease in SGLT2 expression and in the number of SGLT2-positive tubules in treated animals, suggesting that the treatment may modulate SGLT2 inhibition. Overall, 4PHF emerges as a promising therapeutic candidate for diabetes mellitus, as it reduces renal SGLT2 expression, improves metabolic dysfunction, and attenuates diabetes-induced hepatic and renal damage.

Scientia PharmaceuticaVol. 94(4)
Consejo Estatal de Ciencia y Tecnología de Jalisco
Good health and well-being
Natural Antidiabetic Agents Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon